One-liner#

Peripheral neuropathy management centers on identifying reversible causes (diabetes, B12 deficiency, alcohol, medications), treating the underlying etiology, and providing symptomatic relief with gabapentin/pregabalin or duloxetine while emphasizing foot care and fall prevention.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

Clinical diagnosis based on:

• Symptoms: numbness, tingling, burning, pain in distal extremities
• Signs: distal sensory loss (stocking-glove distribution), reduced/absent ankle reflexes
• Supportive testing: EMG/NCS confirms and characterizes neuropathy

Classification by fiber type:

• Large fiber: numbness, imbalance, reduced vibration/proprioception, absent reflexes
• Small fiber: burning pain, temperature sensitivity, autonomic symptoms; normal EMG/NCS
• Mixed: combination of above (most common)

Classification by pathology:

• Axonal: most common; length-dependent; distal-to-proximal progression
• Demyelinating: often inflammatory; proximal weakness; requires neurology referral
• Mixed axonal-demyelinating: features of both

Epidemiology#

Prevalence is 2-8% in general population; increases with age to 15% in those >40 years. Diabetic neuropathy affects 50% of patients with diabetes. Most common causes: diabetes (30-40%), idiopathic (25-30%), alcohol (10%), B12 deficiency, medications, hereditary. Annual incidence of diabetic neuropathy is 2% per year of diabetes duration.

Risk factors:

• Diabetes (duration, poor glycemic control)
• Alcohol use disorder
• B12 deficiency (metformin use, pernicious anemia, vegan diet)
• Chronic kidney disease
• Chemotherapy (platinum agents, taxanes, vinca alkaloids)
• HIV
• Hereditary (Charcot-Marie-Tooth)

Pathophysiology#

Mechanism (clinical understanding)#

Axonal neuropathy (most common): Damage occurs to the nerve fiber (axon) itself. Because the longest nerves are most vulnerable, symptoms start distally and progress proximally—the “dying back” phenomenon. This explains the stocking-glove distribution. Causes include metabolic (diabetes, uremia), toxic (alcohol, chemotherapy), nutritional (B12), and ischemic injury.

Demyelinating neuropathy: Damage to the myelin sheath slows nerve conduction. Often inflammatory/autoimmune (Guillain-Barré syndrome, CIDP). Presents with more proximal weakness, areflexia, and motor involvement. EMG/NCS shows slowed conduction velocities. Requires neurology referral—may respond to immunotherapy.

Small fiber neuropathy: Affects unmyelinated C fibers and thinly myelinated Aδ fibers. Causes burning pain, temperature sensitivity, and autonomic dysfunction. EMG/NCS is normal (tests large fibers only). Diagnosis requires skin biopsy showing reduced intraepidermal nerve fiber density. Common in diabetes, prediabetes, and idiopathic cases.

Diabetic neuropathy mechanism: Hyperglycemia causes nerve damage through multiple pathways: polyol pathway activation (sorbitol accumulation), advanced glycation end products, oxidative stress, and microvascular ischemia. This explains why tight glucose control slows progression but doesn’t reverse established damage—the injury is cumulative.

How to explain to patients#

Your nerves are like electrical wires that carry signals between your brain and your body. In peripheral neuropathy, the nerves in your hands and feet are damaged and don’t work properly.

Think of it like a frayed electrical cord. When the insulation is damaged, the signals don’t travel correctly. This causes numbness, tingling, or pain. The longest nerves—the ones going to your feet—are affected first because they’re the most vulnerable.

The most common cause is diabetes. High blood sugar over time damages the nerves. Other causes include vitamin deficiencies, alcohol, certain medications, and sometimes we can’t find a specific cause.

The good news is that if we find and treat the cause early, we can often stop it from getting worse. We also have medications that can help with the pain and discomfort.

Clinical presentation#

Characteristic symptoms#

Sensory symptoms (most common):

• Numbness: “feet feel like they’re wrapped in cotton”
• Tingling/paresthesias: “pins and needles”
• Burning pain: often worse at night; may be severe
• Electric shock sensations
• Hypersensitivity: pain from light touch (allodynia)
• Cold or hot sensations
• “Walking on pebbles” sensation

Motor symptoms (less common in typical polyneuropathy):

• Weakness: foot drop, difficulty with fine motor tasks
• Muscle cramps
• Atrophy: intrinsic foot muscles, thenar/hypothenar eminences

Autonomic symptoms (suggest small fiber involvement):

• Dry skin, reduced sweating in feet
• Orthostatic hypotension
• Gastroparesis, constipation
• Erectile dysfunction
• Urinary retention

Distribution:

• Stocking-glove: starts in toes, progresses to feet, then hands (when symptoms reach mid-calf)
• Length-dependent: longest nerves affected first
• Symmetric: both sides equally affected

Physical exam findings#

Sensory exam:

• Reduced light touch (cotton wisp) distally
• Reduced pinprick sensation distally
• Reduced vibration sense (128 Hz tuning fork) at great toe, ankle
• Reduced proprioception (toe position sense)
• 10-g monofilament: inability to feel = loss of protective sensation

Motor exam:

• Weakness of toe extensors (EHL), ankle dorsiflexors (foot drop in severe cases)
• Intrinsic foot muscle atrophy (guttering between metatarsals)
• Hand intrinsic weakness (late finding)

Reflexes:

• Ankle reflexes reduced or absent (earliest reflex change)
• Knee reflexes usually preserved until advanced

Gait:

• Wide-based, cautious gait
• Positive Romberg (worse with eyes closed)
• Steppage gait if foot drop present

Foot inspection:

• Calluses, deformities (hammertoes, Charcot foot)
• Skin changes: dry, shiny, hairless
• Ulcers (may be painless due to sensory loss)
• Nail changes

Red flags#

Require urgent evaluation:

• Rapid progression (days to weeks): consider GBS, vasculitis
• Significant motor weakness: may indicate demyelinating process
• Asymmetric presentation: consider mononeuritis multiplex, vasculitis
• Proximal weakness: consider CIDP, myopathy
• Autonomic crisis: severe orthostatic hypotension, arrhythmias
• Associated systemic symptoms: weight loss, fever (consider malignancy, vasculitis)

Suggest alternative diagnosis:

• Upper motor neuron signs (hyperreflexia, Babinski): consider myelopathy
• Cranial nerve involvement: consider GBS, sarcoidosis
• Skin rash with neuropathy: consider vasculitis, sarcoidosis
• Mononeuropathy pattern: consider entrapment, compression

Diagnostic workup#

Initial evaluation#

First-line labs (order for all patients with suspected polyneuropathy):

Second-line labs (if initial workup negative or atypical features):

Confirmatory testing#

EMG/Nerve conduction studies (NCS):

When to order:

• Diagnostic uncertainty (is it neuropathy vs radiculopathy vs myelopathy?)
• Weakness present (need to assess severity)
• Atypical features (asymmetric, rapid progression, proximal)
• Before specialist referral
• Not responding to treatment as expected
• Medicolegal documentation needed

What EMG/NCS tells you:

• Confirms neuropathy vs other localization
• Axonal vs demyelinating (guides differential)
• Severity (mild, moderate, severe)
• Distribution (length-dependent vs non-length-dependent)

Interpretation:

• Axonal: reduced amplitudes, relatively preserved velocities
• Demyelinating: slowed velocities, prolonged distal latencies, conduction block
• Mixed: features of both

Skin biopsy (for small fiber neuropathy):

• Order when: burning pain with normal EMG/NCS
• Measures intraepidermal nerve fiber density (IENFD)
• Reduced IENFD confirms small fiber neuropathy
• Usually done by neurology or dermatology

When to refer for specialist workup#

Refer to neurology:

• Diagnostic uncertainty after initial workup
• EMG/NCS shows demyelinating pattern (may need immunotherapy)
• Rapid progression or significant weakness
• Asymmetric or non-length-dependent pattern
• Suspected small fiber neuropathy (for skin biopsy)
• Monoclonal protein on SPEP (may need hematology co-management)
• Not improving despite treating identified cause
• Consideration of immunotherapy (IVIG, plasmapheresis)

What NOT to order#

• Extensive autoimmune panels without clinical suspicion: low yield, expensive, false positives cause anxiety
• Genetic testing without family history or specific phenotype: expensive, rarely changes management in primary care
• Lumbar puncture routinely: only if inflammatory/demyelinating neuropathy suspected
• MRI of spine unless myelopathy or radiculopathy suspected: neuropathy is a clinical/EMG diagnosis
• Heavy metal levels without exposure history: very rare cause; low yield
• Nerve biopsy in primary care: invasive; reserved for vasculitis or amyloidosis workup by neurology

Treatment#

Goals of therapy#

Primary goals:

• Identify and treat reversible causes
• Slow or halt progression
• Relieve symptoms (pain, paresthesias)
• Prevent complications (falls, foot ulcers, amputations)
• Maintain function and quality of life

Treatment targets:

Non-pharmacologic management#

Treat underlying cause (most important):

• Diabetes: optimize glycemic control (A1c <7%); tight control slows progression by 60%
• B12 deficiency: replacement therapy (see below)
• Alcohol: cessation; nutritional supplementation
• Medication-induced: discontinue offending agent if possible
• Uremia: optimize dialysis; consider transplant evaluation

Foot care (critical for diabetic neuropathy):

• Daily foot inspection (use mirror for soles)
• Wash feet daily; dry thoroughly between toes
• Moisturize (avoid between toes)
• Never walk barefoot
• Proper footwear: well-fitting, protective; diabetic shoes if deformity
• Cut nails straight across; see podiatrist if unable
• No heating pads or hot water bottles (can’t feel burns)
• Report any cuts, blisters, or color changes immediately

Fall prevention:

• Home safety assessment: remove throw rugs, improve lighting, install grab bars
• Assistive devices: cane or walker if balance impaired
• Physical therapy: balance training, strengthening
• Review medications: reduce sedatives, anticholinergics
• Vision correction

Physical therapy:

• Balance and gait training
• Strengthening exercises
• Desensitization techniques for allodynia
• TENS (transcutaneous electrical nerve stimulation): may help some patients

Lifestyle modifications:

• Regular exercise (improves symptoms and glucose control)
• Smoking cessation (worsens microvascular disease)
• Limit alcohol (even if not primary cause)
• Healthy diet

Pharmacologic management#

B12 replacement (if deficient):

Neuropathic pain—First-line agents:

Neuropathic pain—Second-line agents:

Topical agents (adjunctive or for localized pain):

Combination therapy:

• If single agent provides partial relief, add agent from different class
• Common combinations: gabapentin + duloxetine, gabapentin + topical lidocaine
• Avoid combining TCAs with duloxetine/venlafaxine (serotonin syndrome risk)

Medications to avoid:

• Opioids: not recommended for chronic neuropathic pain; addiction risk, limited efficacy
• NSAIDs: ineffective for neuropathic pain
• Benzodiazepines: no benefit; increase fall risk

Patient counseling points#

About neuropathic pain medications:

• “These medications work differently than regular pain relievers. They calm down overactive nerves.”
• “It takes 2-4 weeks to see the full effect. Don’t give up too soon.”
• “We start with a low dose and increase slowly to minimize side effects.”
• “The goal is to reduce pain by at least half—complete pain relief is often not realistic.”

About gabapentin/pregabalin:

• “You may feel drowsy or dizzy at first. This usually improves after a week or two.”
• “Take it at bedtime initially. We’ll add daytime doses as you adjust.”
• “Don’t stop suddenly—we need to taper slowly to avoid withdrawal symptoms.”
• “Avoid alcohol—it increases drowsiness.”

About duloxetine:

• “This medication also helps with mood, which is a bonus if you’re feeling down.”
• “Nausea is common the first week. Take it with food.”
• “Don’t stop suddenly—we need to taper to avoid withdrawal symptoms.”

About foot care (for diabetic neuropathy):

• “Check your feet every day. Use a mirror to see the bottoms.”
• “You may not feel injuries because of the numbness. That’s why daily checks are so important.”
• “Never walk barefoot, even at home. A small cut can become a serious infection.”
• “See a podiatrist regularly for nail care and callus removal.”

Monitoring and follow-up#

Initial phase (first 3 months):

• Follow-up 2-4 weeks after starting pain medication (assess tolerability, titrate)
• Follow-up 6-8 weeks (assess efficacy, continue titration)
• Recheck B12 at 2-3 months if replacing

Stable phase:

• Every 3-6 months for symptom assessment and medication review
• Annual comprehensive foot exam (monofilament, visual inspection)
• Annual labs: A1c (if diabetic), B12 (if on metformin or history of deficiency)

What to monitor:

• Pain scores (0-10 scale)
• Functional status (walking, sleep, daily activities)
• Medication side effects
• Foot exam findings
• Falls
• Glycemic control (if diabetic)

Patient education#

What is this condition?#

Peripheral neuropathy means the nerves in your hands and feet are damaged. These nerves carry signals for feeling and movement. When they’re damaged, you may feel numbness, tingling, burning, or pain.

The most common cause is diabetes. High blood sugar over many years damages the nerves. Other causes include vitamin B12 deficiency, alcohol, certain medications, and kidney disease. Sometimes we can’t find a specific cause.

Neuropathy usually starts in the feet and may spread to the hands over time. The longest nerves are affected first, which is why symptoms start in the toes.

What you can do#

Check your feet every day. Look for cuts, blisters, redness, or swelling. Use a mirror to see the bottoms of your feet. Because you may not feel injuries, you need to look for them.

Protect your feet. Wear shoes or slippers at all times, even indoors. Make sure your shoes fit well and don’t rub. Never walk barefoot.

Keep your blood sugar under control if you have diabetes. Good control can slow down nerve damage.

Take your medications as prescribed. Pain medications for neuropathy take time to work. Give them at least 2-4 weeks before deciding if they help.

Prevent falls. Remove throw rugs, improve lighting, and use handrails. Consider a cane if you feel unsteady.

Avoid alcohol. Even moderate drinking can worsen nerve damage.

When to seek care#

Call your doctor if you notice a cut, blister, or sore on your foot that isn’t healing.

Call if your pain is getting worse or your medications aren’t helping.

Call if you notice new weakness in your feet or hands, or if you’re having more falls.

Call if you have new symptoms like dizziness when standing up, or problems with digestion or urination.

Go to urgent care or the emergency room if you have a foot wound with redness spreading up your leg, fever, or pus. This could be a serious infection.

Questions to ask your doctor#

• What is causing my neuropathy?
• Are there any tests I need?
• What can I do to prevent it from getting worse?
• What are my options for pain relief?
• Should I see a foot doctor (podiatrist)?
• Do I need special shoes?
• How often should I have my feet checked?
• Should I see a neurologist?

Prognosis and monitoring#

Expected course#

With treatment of underlying cause:

• Diabetic neuropathy: tight glucose control slows progression by 60%; rarely reverses established damage
• B12 deficiency: symptoms may improve over 6-12 months with replacement; severe/prolonged deficiency may not fully reverse
• Alcohol-related: may stabilize or improve with abstinence and nutrition
• Medication-induced: often improves after stopping offending agent (months to years)

Without treatment:

• Progressive sensory loss
• Increased fall risk
• Foot ulcers and amputations (diabetic neuropathy)
• Chronic pain affecting quality of life

Natural history:

• Most polyneuropathies progress slowly over years
• Symptoms typically start in feet, spread to ankles, then hands (when symptoms reach mid-calf)
• Motor involvement is late and suggests more severe disease
• Autonomic symptoms indicate widespread nerve involvement

Monitoring parameters#

Complications to watch for#

Foot complications (diabetic neuropathy):

• Foot ulcers: occur in 15-25% of diabetics; often painless due to sensory loss
• Infections: cellulitis, osteomyelitis; can progress rapidly
• Charcot foot: bone/joint destruction from repeated unnoticed trauma
• Amputation: diabetes is leading cause of non-traumatic amputation

Falls and injuries:

• Impaired proprioception and balance increase fall risk
• Falls can cause fractures, head injuries
• Fear of falling leads to reduced activity and deconditioning

Autonomic complications:

• Orthostatic hypotension: dizziness, syncope
• Gastroparesis: nausea, bloating, erratic glucose control
• Neurogenic bladder: urinary retention, recurrent UTIs
• Erectile dysfunction

Medication-related:

• Gabapentin/pregabalin: sedation, cognitive impairment, edema, falls
• TCAs: anticholinergic effects, cardiac conduction abnormalities
• Duloxetine: hypertension, hepatotoxicity (rare)

Special populations#

Elderly/geriatric#

Presentation differences:

• May attribute symptoms to “normal aging”—screen actively
• Higher prevalence of idiopathic neuropathy
• More likely to have multiple contributing factors (diabetes + B12 + medications)
• Falls are a major concern

Treatment considerations:

• Start low, go slow with all medications
• Gabapentin: start 100 mg QHS; titrate slowly; watch for sedation, cognitive impairment, falls
• Pregabalin: same cautions; may cause more edema
• Avoid TCAs (amitriptyline, nortriptyline): anticholinergic burden, falls, cardiac effects (Beers criteria)
• Duloxetine: reasonable option; watch for hyponatremia, falls
• Topical agents: preferred for localized pain; no systemic effects
• Lidocaine patches: safe, well-tolerated in elderly

Polypharmacy concerns:

• Review all medications for neuropathy-causing drugs
• Gabapentinoids interact with CNS depressants
• TCAs have multiple drug interactions
• Simplify regimens when possible

Fall prevention is critical:

• Home safety assessment
• Physical therapy for balance
• Assistive devices as needed
• Minimize sedating medications

Chronic kidney disease#

Uremic neuropathy:

• Occurs in advanced CKD (eGFR <15-20)
• Improves with dialysis; may resolve after transplant
• Restless legs syndrome common

Medication adjustments:

Key points:

• Gabapentin and pregabalin accumulate in CKD—significant dose reduction required
• Duloxetine: avoid if eGFR <30
• TCAs: no renal adjustment but anticholinergic effects more problematic
• Topical agents: safe, preferred in CKD
• B12 deficiency common in CKD—check and replace

Other populations#

Diabetic patients:

• Most common cause of neuropathy; 50% of diabetics affected
• Tight glucose control (A1c <7%) slows progression by 60%
• Annual monofilament screening for all diabetics
• Foot care education at every visit
• Consider SGLT2 inhibitors and GLP-1 agonists (may have neuroprotective effects)
• Metformin can cause B12 deficiency—check B12 annually

Chemotherapy-induced peripheral neuropathy (CIPN):

• Common with platinum agents, taxanes, vinca alkaloids, bortezomib
• May be dose-limiting toxicity
• Often improves after stopping chemotherapy (months to years)
• Duloxetine has best evidence for CIPN pain
• Coordinate with oncology before starting treatment

HIV-associated neuropathy:

• Can be from HIV itself or antiretroviral medications (especially older NRTIs)
• Coordinate with HIV specialist
• Standard neuropathic pain agents effective

Alcohol-related neuropathy:

• Abstinence is essential
• Thiamine replacement: 100 mg daily
• Multivitamin supplementation
• May improve with abstinence and nutrition

Pregnancy:

• Gabapentin: limited data; use only if benefit outweighs risk
• Pregabalin: avoid (teratogenic in animal studies)
• Duloxetine: avoid in third trimester (neonatal withdrawal)
• TCAs: relatively safe; nortriptyline preferred
• Topical agents: safe
• B12 replacement: safe and important

When to refer#

Specialist referral criteria#

Refer to neurology:

• Diagnostic uncertainty after initial workup
• EMG/NCS shows demyelinating pattern (may need IVIG, plasmapheresis)
• Rapid progression (weeks) or significant motor weakness
• Asymmetric or non-length-dependent pattern
• Suspected small fiber neuropathy (for skin biopsy)
• Monoclonal gammopathy on SPEP (may need hematology)
• Not improving despite treating identified cause
• Autonomic neuropathy with significant symptoms
• Consideration of immunotherapy

Refer to podiatry:

• All diabetic patients with neuropathy (at least annually)
• History of foot ulcer or amputation
• Foot deformity (Charcot, hammertoes, bunions)
• Unable to perform self-care (nail trimming, callus care)
• Need for diabetic shoes or orthotics

Refer to endocrinology:

• Diabetes with A1c persistently >9% despite treatment
• Complex insulin regimens needed
• Autonomic neuropathy affecting glucose control (gastroparesis)

Refer to pain management:

• Refractory pain despite trials of multiple agents
• Consideration of spinal cord stimulation
• Need for multidisciplinary pain program

Urgency levels#

Routine (weeks):

• Stable symptoms, diagnostic workup complete
• Optimization of pain management
• Annual podiatry visit for diabetic patients

Urgent (days to 1-2 weeks):

• Rapid progression of symptoms
• New significant weakness
• Foot wound in diabetic patient
• Suspected inflammatory neuropathy (GBS, CIDP)

Emergent (same day/ED):

• Acute foot infection with spreading cellulitis, fever
• Suspected GBS with respiratory involvement
• Severe autonomic dysfunction (syncope, arrhythmia)
• Acute limb ischemia

Smartphrase snippets#

Peripheral neuropathy, stable: Peripheral neuropathy, [diabetic/idiopathic/B12-related], stable on current regimen. Pain controlled with [medication]; foot exam shows no ulcers. Continue current treatment and reinforce foot care; f/u 3-6 months.

Peripheral neuropathy, starting treatment: Peripheral neuropathy with neuropathic pain, starting [gabapentin 100 mg QHS / duloxetine 30 mg daily]. Discussed foot care, fall prevention, and medication titration plan. F/u 2-4 weeks to assess tolerability.

Peripheral neuropathy, new diagnosis: New diagnosis of peripheral neuropathy with stocking-glove distribution; workup shows [A1c X, B12 X]. Most likely etiology is [diabetic/idiopathic/B12 deficiency]; starting [treatment]. F/u 4-6 weeks.

Diabetic neuropathy, annual foot exam: Annual diabetic foot exam: monofilament [intact/reduced], no ulcers or deformities noted. Reinforced daily foot inspection and proper footwear. Podiatry referral [yes/no].

Related pages#

Complaint pages#

• Numbness / Tingling — symptom-based approach to numbness and tingling differential
• Weakness — evaluation of motor symptoms
• Gait Instability / Falls — balance and fall evaluation in neuropathy patients

Problem pages#

• Type 2 Diabetes — diabetic neuropathy prevention and glucose management
• Hypothyroidism — thyroid-related neuropathy
• Chronic Kidney Disease — uremic neuropathy management (coming soon)